Low‐dose methotrexate kinetics in arthritis

[1]  J. Paxton.  THE PROTEIN BINDING AND ELIMINATION OF METHOTREXATE AFTER INTRAVENOUS INFUSIONS IN CANCER PATIENTS , 1982, Clinical and experimental pharmacology & physiology.

[2]  W. Evans,et al.  High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. , 1980, Cancer treatment reports.

[3]  M. Weisman,et al.  Methotrexate pharmacokinetics after intraarticular injection in patients with rheumatoid arthritis. , 1980, Arthritis and rheumatism.

[4]  R. Willkens,et al.  Low dose pulse methotrexate therapy in rheumatoid arthritis. , 1980, The Journal of rheumatology.

[5]  D. Shen,et al.  Clinical Pharmacokinetics of Methotrexate , 1978, Clinical pharmacokinetics.

[6]  F. Rowell,et al.  A rapid, sensitive and specific radioimmunoassay for methotrexate. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[7]  W. Bleyer,et al.  Methotrexate: clinical pharmacology, current status and therapeutic guidelines. , 1977, Cancer treatment reviews.

[8]  P. Engstrom,et al.  Comparison of serum concentrations of methotrexate after various routes of administration , 1975, Cancer.

[9]  M. Berman,et al.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. , 1975, Cancer chemotherapy reports.

[10]  B. Hoogstraten,et al.  Effect of route of administration and effusions on methotrexate pharmacokinetics. , 1974, Cancer research.

[11]  B. Hoogstraten,et al.  Pharmacokinetics of methotrexate , 1973, Clinical pharmacology and therapeutics.

[12]  B. Chabner,et al.  Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. , 1973, The Journal of clinical investigation.

[13]  E. Henderson,et al.  The effect of organic acids on renal clearance of methotrexate in man , 1969, Clinical pharmacology and therapeutics.